Drawing on 35 years of experience in the development and production of high-temperature ceramic fibre, RATH is always looking ...

FDA approved Ryoncil ® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

RHI Magnesita acquired U.S.-based Resco Group for $410 million. The move enhances local production and supply chain security for critical industries.

Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced ...

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development ...

Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced stage, often with metastatic disease.

Below is a detailed analysis of the two drugs secured by Cosmos Health. Abstract #1: ESTERS OF STEROIDAL LACTAM AND BIS (2-CHLOROETHYL) AMINOPHENOXY PROPANOIC ACID DERIVATIVES; Patent International ...

This variety of monolithic refractories has been specially formulated for aluminum contact. Now, the Fast Dry technology can be seamlessly integrated into the ALKON ® range. Previously, fast-drying ...